Izokibep Fails in Phase 2b/3 Hidradenitis Suppurativa Trial
Acelyrin's IL-17A inhibitor, izokibep, did not meet the primary endpoint in a phase 2b/3 trial for hidradenitis suppurativa treatment, with 39% of patients on once-weekly 160 mg achieving HiSCR75 at 16 weeks vs. 29% on placebo. Despite high discontinuation rates and unexpected placebo response, izokibep showed potential in HiSCR100 and has an ongoing phase 3 trial.
Related Clinical Trials
Reference News
Izokibep Fails in Phase 2b/3 Hidradenitis Suppurativa Trial
Acelyrin's IL-17A inhibitor, izokibep, did not meet the primary endpoint in a phase 2b/3 trial for hidradenitis suppurativa treatment, with 39% of patients on once-weekly 160 mg achieving HiSCR75 at 16 weeks vs. 29% on placebo. Despite high discontinuation rates and unexpected placebo response, izokibep showed potential in HiSCR100 and has an ongoing phase 3 trial.